Galectin-3 and matrix metalloproteinases 2 and 9 in peripheral blood of gastric cancer patients
Authors:
- Ekaterina A. KorotkovaEKEkaterina A. Korotkova
- Elena S. GershteinEGElena S. Gershtein
- Ekaterina V. SamoilovaESEkaterina V. Samoilova
- Irina O. GoryachevaIGIrina O. Goryacheva
- Aram P. PetrosyanAPAram P. Petrosyan
- Natalia N. ZybinaNZNatalia N. Zybina
- Oleg O. YanushevichOYOleg O. Yanushevich
- Ivan S. StilidiISIvan S. Stilidi
- Nikolay E. KushlinskiiNKNikolay E. Kushlinskii
Open Access
- 10 May 2023
- journal article
- research article
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 51 (1) , 23-31
Abstract
Background: High incidence of gastric cancer (GC), its aggressive clinical course, rapid tumor dissemination, low sensitivity to chemotherapy and lack of reliable laboratory diagnostic criteria urgently require a search for the most informative markers associated with key biologic properties of the tumors. Aim: Comparative analysis of galectin-3, matrix metalloproteinase (MMP)-2, and MMP-9 levels in peripheral blood of GC patients and healthy donors, assessment of association of these markers with clinical morphological characteristics of the disease, and prognosis of overall and relapse-free survival. Materials and methods: Sixty (60) primary treatment-nave GC patients (38 men, 22 women) aged 29 to 81 years and 90 healthy donors compatible with their age and sex were included into the study. Galectin-3 was measured in EDTA plasma, MMP-2 and MMP-9 in serum with standard direct enzyme immunoassay kits "Human MMP-2 (total)", "Human MMP-9 (total)", "Human Galectin-3" (RD Systems, USA). Results: Plasma galectin-3 concentration in the GC patients was significantly higher than in the healthy controls (median 12.9 and 10.6 ng/ml, respectively; p 0.0001). No difference in serum MMP-9 levels between GC patients and control subjects were found, while MMP-2 level in the control group was significantly higher, than in the GC patients (p = 0.039). No association between galectin-3, MMP-2, and MMP-9 blood levels in the GC patients could be identified. In contrast to GC patients, there was a positive correlation of plasma galectin-3 with age in the control group (rs = 0.51, p 0.005). No associations between the biomarkers levels in blood and clinical and morphological characteristics of GC were established, except MMP-9 being higher at Т4а invasion depth as compared to the earlier Т2 level. Marked differences in the overall survival depending on plasma galectin-3 levels were found, with the cut-off level of 12.9 ng/ml: the 5-year overall survival in the patients with low galectin-3 was better, than in those with its higher level (50 and 43%, respectively; however, the difference was non-significant, р 0.1). Both overall and relapse-free survival of the GC patients was higher in those with low ( 212 ng/ml) serum MMP-2: the 5-year overall survival in this group comprised 60% versus 23% in the patients with higher MMP-2 (p = 0.018). The difference in relapse-free survival was non-significant. Serum MMP-9 levels had no significant impact on the survival of GC patients. Conclusion: The ambiguous data on the clinical role of galectin-3, MMP-2, MMP-9 in GC obtained in this study indicate the necessity of further investigation of their possible utility for the diagnostics and prognosis of treatment results.Keywords
This publication has 25 references indexed in Scilit:
- Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patientsAdvances in Medical Sciences, 2013
- Galectin‐3 expression in thyroid fine needle cytology (t‐FNAC) uncertain cases: Validation of molecular markers and technology innovationJournal of Cellular Physiology, 2012
- Galectin-3 – A jack-of-all-trades in cancerCancer Letters, 2011
- Galectin-3 Facilitates Cell Motility in Gastric Cancer by Up-Regulating Protease-Activated Receptor-1(PAR-1) and Matrix Metalloproteinase-1(MMP-1)PLOS ONE, 2011
- Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancerClinical & Experimental Metastasis, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Focus on Molecules: Galectin-3Experimental Eye Research, 2011
- Galectin-3 Cleavage: A Novel Surrogate Marker for Matrix Metalloproteinase Activity in Growing Breast CancersCancer Research, 2007
- Galectin-3 regulates myofibroblast activation and hepatic fibrosisProceedings of the National Academy of Sciences of the United States of America, 2006
- Regulation of Cellular Adhesion to Extracellular Matrix Proteins by Galectin-3Biochemical and Biophysical Research Communications, 1998